MADAM-6
| Clinical data | |
|---|---|
| Other names | 6-Methyl-MDMA; 2,N-Dimethyl-4,5-methylenedioxyamphetamine |
| Routes of administration | Oral[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H17NO2 |
| Molar mass | 207.273 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MADAM-6, also known as 2,N-dimethyl-4,5-methylenedioxyamphetamine or as 6-methyl-MDMA, is a drug of the phenethylamine, amphetamine, and MDxx families related to MDMA.[1][2]
Use and effects
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MADAM-6's dose as greater than 280 mg orally and its duration as unknown.[1] MADAM-6 produced few to no effects at tested doses and Shulgin described it as "not active".[1]
History
MADAM-6 was first described in the literature by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.[1]
Research
MADAM-6 has been studied for its potential antiparkinsonian effects.[3] However, no clinical trials suggest the drug is effective against Parkinson's disease.
See also
References
- ^ a b c d e f Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. MADAM-6 entry
- ^ Patt M, Gündisch D, Wüllner U, Blocher A, Kovar KA, Machulla HJ (1999). "N-[11C]methyl-3,4-methylenedioxyamphetamine (Ecstasy) and 2-methyl-N-[11C]methyl-4,5-methylenedioxyamphetamine: Synthesis and biodistribution studies". Journal of Radioanalytical and Nuclear Chemistry. 240 (2): 535–540. doi:10.1007/BF02349410. S2CID 96272983.
- ^ US patent 2015025063, Caron MG, Sotnikova TD, Gainetdinov RR, "Antiparkinsonian Action Of Phenylisopropylamines", published 2014-09-30, issued 2015-01-22, assigned to Duke University